Peer-reviewed journal spotlights differentiated pharmacology and therapeutic promise for neuropathic pain
MIRA Pharmaceuticals (MIRA), a clinical-stage biotech firm focused on developing innovative treatments for neurologic, neuropsychiatric, and metabolic disorders, announced a significant milestone today: the first peer-reviewed manuscript detailing its lead drug candidate, Ketamir-2, has been accepted for publication in Frontiers in Pharmacology.
Authored by Dr. Itzchak Angel, MIRA’s Chief Scientific Advisor, the article—titled “KETAMIR-2, A NEW MOLECULAR ENTITY AND NOVEL KETAMINE ANALOG”—presents compelling preclinical data supporting the pharmacological uniqueness of Ketamir-2. Currently in an ongoing Phase 1 clinical trial for neuropathic pain, the compound is positioned as a next-generation central nervous system (CNS) therapeutic.
The acceptance of the manuscript marks a key step in validating MIRA’s approach to reengineering ketamine’s therapeutic profile. Unlike traditional ketamine, Ketamir-2 was specifically designed to address its known limitations—including poor oral bioavailability, dissociative side effects, and non-specific receptor activity.
Publication in a respected, peer-reviewed journal not only underscores the scientific rigor behind MIRA’s drug development program, but also provides third-party validation from independent experts. The company views this as a strong endorsement of Ketamir-2’s differentiated pharmacology and its potential to offer a safer, more targeted treatment for patients suffering from chronic neuropathic pain.
As MIRA continues its clinical development efforts, the scientific spotlight on Ketamir-2 may attract broader attention from the medical and investment communities, further advancing its mission to deliver transformative therapies for hard-to-treat CNS disorders.
You might like this article:AMD’s Growth Engine Accelerates as Piper Sandler Raises Price Target to $140
